EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Physiologically Based Pharmacokinetic Modeling in Patients With Hepatic Impairment: Are Changes in Bosutinib Exposure Profiles Driven by Altered Absorption or Distribution?

Chieko Muto iD, Hannah M Jones, Shinji Yamazaki iD

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Chieko Muto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pfizer R&D Japan, Tokyo, Japan. Hauptthemen laut MEDLINE: Aniline Compounds, Nitriles, Quinolines, Models, Biological. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor and has been approved for the treatment of patients with Ph + chronic myelogenous leukemia. Bosutinib is a substrate of P‐glycoprotein (P‐gp) in vitro and is predominantly metabolized by CYP3A4 in humans with minimal urinary excretion. We present our perspective on using physiologically based pharmacokinetic modeling to understand the atypical changes in oral exposure of bosutinib, a CYP3A and P‐gp substrate, in hepatic impairment patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsNitrilesQuinolinesModels, BiologicalProtein Kinase InhibitorsLiver DiseasesHumansCytochrome P-450 CYP3ALeukemia, Myelogenous, Chronic, BCR-ABL PositiveAdministration, OralATP Binding Cassette Transporter, Subfamily B, Member 1Tyrosine Kinase Inhibitors

Stichwörter der Autor:innen

CYP3Aglycoproteinshepatic impairmentphysiologically‐based pharmacokinetic modeling

Substanzen

bosutinibAniline CompoundsNitrilesQuinolinesCytochrome P-450 CYP3AProtein Kinase InhibitorsCYP3A4 protein, humanATP Binding Cassette Transporter, Subfamily B, Member 1Tyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Clinical Pharmacology, Pfizer R&D Japan, Tokyo, Japan.
  • Simcyp Division, Certara UK Limited, Sheffield, UK.

ORCID-Profile: Chieko Muto, Shinji Yamazaki

Zitieren

APA

Muto, C., Jones, H. M., & Yamazaki, S. (2026). Physiologically Based Pharmacokinetic Modeling in Patients With Hepatic Impairment: Are Changes in Bosutinib Exposure Profiles Driven by Altered Absorption or Distribution?. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70179

Vancouver

Muto C, Jones HM, Yamazaki S. Physiologically Based Pharmacokinetic Modeling in Patients With Hepatic Impairment: Are Changes in Bosutinib Exposure Profiles Driven by Altered Absorption or Distribution?. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70179

BibTeX
@article{Muto2026,
  author = {Muto, Chieko and Jones, Hannah M and Yamazaki, Shinji},
  title = {Physiologically Based Pharmacokinetic Modeling in Patients With Hepatic Impairment: Are Changes in Bosutinib Exposure Profiles Driven by Altered Absorption or Distribution?},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70179}
}
Kostenlos starten →